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2012.10.0Abstract Background: Breast cancer (BC) is a major worldwide health care problem that mostly
afﬂicts the elderly population in the more developed countries. It is not known how common is
breast cancer among elderly Egyptian patients and whether this differs from the disease in younger
patients.
Aims: To study the clinico-pathological features of BC in elderly Egyptian patients (P65 years of
age) among the population of an Egyptian Governorate, Gharbiah, and to compare these features
with those of younger patients (<65 years).
Methods: This is a cross sectional study that compares elderly BC (EBC) and the non-elderly BC
(NEBC) using the information from the Gharbiah Population-based Cancer registry (GPCR) dur-
ing the years 1999–2007.
Results: Out of 6078 BCs, 12% were EBCs and 88% were NEBCs. Between 1999 and 2007, the
crude incidence rate (CIR, per 100,000 populations) of EBC increased from 47 to 71 and that of
NEBC increased from 16 to 17. Compared to NEBC patients, EBC patients were more likely to
have a positive family history and present with a distant disease and less likely to present with a
localized disease. EBCs were more likely to have lung metastases and less likely to have liver metas-
tases. Histology, grade, hormone and HER-2 receptor statuses were comparable in both groups.1000943.
(A.A. Zeeneldin).
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6 A.A. Zeeneldin et al.Apart from hormonal therapies, the elderly were less likely to receive surgery, radiotherapy or
chemotherapy.
Conclusion: EBC patients in Egypt present with advanced disease and are less likely to receive sur-
gery, radiotherapy or chemotherapy compared to NEBC patients.
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Breast cancer is by far the most common cancer among women
of both developed and developing countries accounting for
22.9% of all female cancers. It is also the leading cause of can-
cer death in females accounting for 13.7% of their cancer-
related mortality. The favorable incidence to mortality ratio
(3:1) can be attributed to the more favorable survival in devel-
oped regions (3.7:1) than the less developed regions (2.7:1) [1].
In Egypt, breast cancer is estimated to be the most common
cancer among females accounting for 37.7% of their total with
12,621 new cases in 2008. It is also the leading cause of cancer-
related mortality accounting for 29.1% of their total with 6546
deaths. The incidence to mortality ratio is poor (1.9:1) [1].
These estimates are conﬁrmed in many regional Egyptian can-
cer registries [2,3] as well as in hospital-based frequencies [4].
Breast cancer is an age-related disease. Second to female
gender, advancing age is the most important risk factor for
breast cancer. Age interactions are frequently reported in stud-
ies that examine etiology, prognosis and treatment [5–7]. In
USA, approximately 50% of breast cancers occurs in women
65 years of age or older and more than 30% occurs after the
age of 70 [8]. Moreover, older women are the fastest growing
segment in developed countries [9,10] and they will represent
an increasing cohort of patients with newly diagnosed breast
cancer as well as cancer survivors [11]. In Egypt, the peak inci-
dence of breast cancer occurs in the age group of 40–59 years
[2–4]. Elderly Egyptian population aged 65 years or more in-
creased from 3.4% in 1996 to 3.7% in 2006 [12]. With the
improvement of health care systems, life expectancy (LE) of
the Egyptians is expected to rise markedly. Currently, LE of
Egyptian males and females at birth is 70 years and 76 years,
respectively [13]. It is expected that people aged 60 years or
more will increase from 4.6 millions in 2000 to 23.7 millions
in 2050 [14]. Breast cancer among elderly Egyptians is expected
to rise markedly in the future.
These older breast cancer survivors are quite a heteroge-
neous group especially with respect to multiple co-morbid con-
ditions [15]. Compared with younger women, older women
have more ER and PR and less HER-2 expression. Tumor size
and nodal involvement increase with age attributable not only
to delayed diagnosis but also to aggressiveness [16]. Barriers
related to age, functional status, and social support can be
associated with less diagnostic activities and less aggressive
treatments with poorer survival [17]. EBC patients are under-
represented in clinical trials and their treatments are largely
extrapolated from trials in younger patients taking in consider-
ation efﬁcacy, expected tolerance, co-morbidities and patients’
preferences. However, the elderly are less likely to undergo sur-
gery, radiotherapy and chemotherapy [17].
Reports on EBC among Egyptians are very scanty, partic-
ularly at the population-based level. Accordingly, it is not
known whether EBC among Egyptians is similar to EBC indifferent world regions and how similar it is to NEBC. The
aims of the current work were to study the clinico-pathological
features of breast cancer among the population of the Gharb-
iah Governorate, Egypt and to compare these features in the
elderly (P65 years of age) with those in younger patients.
Information gained would give an accurate estimate and better
characterization of this disease in Egypt and this can help in
planning its management.
Methods
This is a cross sectional study. The Gharbiah Population-based
Cancer registry (GPCR) was approached to study the patterns
of elderly and non-elderly breast cancer in the Gharbiah Gov-
ernorate, Egypt during the years 1999-2007. As of 1st of Jan-
uary 2012, the number of cases retrieved was 6291. We
excluded 123 cases because of being non-invasive (i.e. CIS in
43 cases) or being of non-carcinoma histology e.g. NHL (80
case). Five cases were excluded as their ages were not docu-
mented and 85 were excluded as they were males. Thus we
were left with 6078 cases of primary invasive breast carcinoma
The following data were extracted for every case whenever
possible: age, year of diagnosis, smoking, family history, later-
ality, SEER stage [18] and TNM stage [19], metastatic sites if
any, histologic type and grade, estrogen, progesterone and Hu-
man Epidermal Growth factor receptors-2 (HER-2) receptor
status, and treatments employed. Population data were ex-
tracted from the website of the Egyptian Central Agency for
Public Mobilization and Statistics [12].Statistical analysis
All statistical analyses were performed using SPSS software,
version 15, Chicago, USA. Differences between the two age
groups were explored using independent t-test or Mann–
Whitney’sU test (for numerical variables) or using Chi-Squared
test or the Fisher’s exact method (for categorical variables). A
two-sided probability (p) of 0.05 or less was considered statisti-
cally signiﬁcant. The crude incidence rate (CIR) of breast cancer
in each age group was calculated by dividing the number of new
cases in a particular year by the corresponding number of per-
sons in the population at risk at that particular year. It is
expressed as an annual rate per 100,000 persons at risk.Results
Out of 6078 cases of invasive BCs registered to GPCR between
1999 and 2007, 730 cases (12%) were elderly and 5348 cases
(88%) were in the non-elderly group. Between the years 1999
and 2007, the CIR of the total BC (per 100,000 population)
of the Gharbiah population increased from 17 to 19 (Fig. 1).
During this period, the increase in CIR of EBC was marked
Figure 1 Annual crude incidence rate (CIR) of breast cancer in
Gharbiah, Egypt during 1999–2007 (per 100,000 populations).
TBC: total breast cancer, EBC: elderly breast cancer, NEBC: non-
elderly breast cancer.
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mild (from 16 to 17). The EBC to NEBC ratio was almost
1:8. EBC increased from 9.4% of total BC burden in 1999 to
14.5% in 2007 (Table 1). The percentage of the elderly popu-
lation in Gharbiah showed a small increase from 3.4% in the
1996 census to 3.8% in the 2006 census. The mean age at diag-
nosis of breast cancer in Egypt increased over the study period;
being 49 years in 1999 and 52 years in 2007. This was mostly
due to an increase in the mean age of the non-elderly patients
(from 47 to 49 years) while that of the elderly was almost stable
at 71 years. In both the groups, the mean tumor size was ﬂuc-
tuating around 4 cm. The median tumor size in EBC patients
was 3.5 cm (IQR, 3–5 cm) compared to 4.0 cm in NEBC pa-
tients (IQR, 3–5 cm, p= 0.3).
Elderly BC patients were more likely to have a negative fam-
ily history of breast cancer (p= 0.07). Elderly and non-elderly
patients had comparable ﬁgures for bilateral breast involve-
ment and inﬂammatory carcinoma features (Table 2). Elderly
and non-elderly patients had comparable ﬁgures for different
histological subtypes (p= 0.56). They were also comparable
for the favorable histologic subtypes (tubular, modularly or
mutinous) being 2.7% and 2.8%, respectively (p= 0.80).Table 1 Breast cancer in Gharbiah Governorate, Egypt between 19
Year Total Population
(·1000)
Elderly population
(·1000)
Total BC
N N % N Agea Sizea
1999 3567 122.0 3.40 619 49 ± 11 4.3 ±
2000 3632 125.3 3.45 585 40 ± 12 4.0 ±
2001 3696 129.4 3.5 619 50 ± 11 3.8 ±
2002 3765 133.7 3.55 623 49 ± 12 3.9 ±
2003 3829 137.8 3.60 675 49 ± 11 4.2 ±
2004 3899 142.3 3.65 701 51 ± 12 4.0 ±
2005 3968 146.8 3.70 722 51 ± 12 4.0 ±
2006 4039 153.5 3.80 763 51 ± 11 4.3 ±
2007 4055 158.1 3.90 771 52 ± 11 4.0 ±
All years 6078 50 ± 12 4.0 ±
BC: breast cancer, NA: data not available.
a mean ± SD in years.Elderly patients were more likely to have grade 1 and 4 tumors
and less likely to have grade 2 tumors (p= 0.002). EBC pa-
tients with positive HER-2 status were 16% compared to
30.8% in NEBC patients (p= 0.189). Both EBC and NEBC
patients had comparable ﬁgures for ER and PR.
At diagnosis, Elderly patients were more likely to have ad-
vanced breast tumors i.e. T4, distant metastases and hence
higher TNM and SEER stages (p< 0.001 for all, Table 2).
The nodal (N) stage and the number of positive axillary LNs
as well as the number of metastatic sites were comparable in
both groups (p= 0.4, 0.2 and 0.9, respectively). Less than
one third of the patients in both groups had N0 disease. The
median number (range) of positive axillary LNs in EBC pa-
tients was 5 (1–34) compared to 5 (1–47) in NEBC patients.
In both the groups, almost 80% of patients with M1 disease
had single metastatic sites. Within the M1 category, 39% of el-
derly patients had visceral metastases compared to 44.5% in
the non-elderly patients (p = 0.36, Fig. 2). Compared to
NEBC patients, EBC patients were less likely to have liver
metastases (13% vs. 25%, p= 0.02) and more likely to have
lung metastases/malignant effusion (28% vs. 19%, p= 0.06).
Both groups had comparable ﬁgures for bone, brain and other
sites of metastases.
The elderly were less likely to undergo surgery, radiother-
apy or chemotherapy as part of their treatment plans
(p< 0.001 for all, Table 3). While the surgical intent was
not different in EBC and NEBC patients, the elderly were less
likely to undergo breast conservation surgery (p= 0.02).
When indicated, the elderly were less likely to undergo adju-
vant radiotherapy (p= 0.002), adjuvant radiotherapy
(p< 0.001). While hormonal therapy usage was comparable
in both the groups, adjuvant hormonal therapy was less likely
to be used in elderly patients (p< 0.001).
Discussion
This is the ﬁrst population-based report on EBC in Egypt and
the ﬁrst to report on such a big number of BC cases (>6000).
While this report focuses on a single district registry (GPCR),
its results can be generalized to the whole country as the pop-
ulation of this region (Gharbiah Governorate) is similar to
that of Egypt. Moreover, GPCR is the most mature registry99 and 2007.
Elderly BC Non-elderly BC
N % Agea Sizea N % Agea Sizea
2.3 58 9.4 70 ± 5 3.8 ± 1.9 561 90.6 47 ± 9 4.3 ± 2.3
3.4 73 12.5 71 ± 6 3.0 ± 1.4 512 87.5 47 ± 9 4.3 ± 3.7
1.6 67 10.8 71 ± 5 3.6 ± 1.9 552 89.2 47 ± 9 3.8 ± 1.6
1.7 74 11.9 71 ± 5 4.8 ± 2.0 549 88.1 47 ± 10 3.8 ± 1.6
2.3 66 9.8 70 ± 5 4.0 ± 2.2 609 90.2 47 ± 9 4.2 ± 2.3
2.0 95 13.6 71 ± 6 3.9 ± 2.0 606 86.4 48 ± 9 4.0 ± 2.0
2.1 90 12.5 71 ± 6 3.4.0 ± 1.2 632 87.5 48 ± 9 4.0 ± 2.2
2.4 95 12.5 71 ± 5 4.6 ± 2.7 668 87.5 48 ± 9 4.2 ± 2.3
2.0 112 14.5 71 ± 5 3.8 ± 1.5 659 85.5 49 ± 9 4.0 ± 2.0
2.0 730 12 71 ± 5 3.9 ± 2.0 5348 88 47 ± 9 4.1 ± 2.2
Table 2 Demographics and histology of elderly (EBC) and non-
elderly breast cancer (NEBC) in Gharbiah, Egypt.
Characteristic EBC NEBC p
N % N %
730 12.0 5348 88.0
Smoking 310 2506
Current or former 3 0.9 7 0.3
None 307 99.1 2499 99.7 0.156
Positive family history 310 2505
Yes 9 4.3 138 5.5
None 301 95.7 2367 94.5 0.070
Laterality 641 5014
Right 304 47.2 2308 46
Left 332 51.8 2666 53.2
Bilateral 5 0.8 40 0.8 0.801
Inﬂammatory BC
Yes 2 0.3 21 0.4
None or unknown 728 99.7 5327 99.6 0.867
Histology 637 5023
IDC, NOS 593 93.1 4626 92.1
IDC, special types 16 2.6 139 2.8
ILC 27 4.3 258 5.1 0.576
Grade 455 4152
1 29 6.4 195 4.7
2 324 71.2 3123 75.2
3 80 17.6 743 17.9
4 22 4.8 91 2.2 0.002
ER 349 2696
Negative 138 39.5 1043 38.7
Positive 211 60.5 1653 61.3 0.758
PR 349 2696
Negative 134 38.4 1091 40.5
Positive 215 61.6 1605 59.5 0.458
HER-2 25 237
Negative 21 84.0 164 69.2
Positive 4 16.0 73 30.8 0.189
T stage
1 40 10.9 332 11.3
2 192 52.5 1763 60.1
3 36 9.8 425 14.5
4 98 26.8 412 14.1 <0.001
N stage
0 123 28.0 1081 27.3
1 143 32.6 1162 29.4
2 114 26.0 1083 27.4
3 59 13.4 627 15.9 0.364
M stage 406 3166
0 311 76.6 2727 86.1
1 95 23.4 439 13.9 <0.001
TNM stage 454 3722
I 23 5.1 158 4.2
II 141 31.1 1435 38.5
III 195 43.0 1690 45.4
IV 95 20.8 439 11.9 <0.001
SEER stage 496 4180
Localized 122 24.6 1066 25.5
Regional 279 56.3 2675 64.0
Distant 95 19.1 439 10.5 <0.001
8 A.A. Zeeneldin et al.in the country, being set in the late nineties, and its data are
widely used by the International Agency for Research on Can-
cer (IARC) to reﬂect cancer incidence in Egypt [3]. Data from
other national registries are in line with those of GPCR [2]. On
the other hand, the retrospective nature of the present study
has its limitations [20]. However, we have done our maximal
efforts to have a well conducted study that gives a clear over-
view of the global situation of BC in the country.
In the current study, the percentage of EBC was 12% of the
total BCs. This is comparable to the 10–18% ﬁgure in many
developing countries including Jordan (10%), Arabs in Israel
(18%) [21], Lebanon (14%) [22], and Nigeria (12.3%) [23].
However, the percentage of EBC in the current study is lower
that of USA (50%), most of the Western European countries
(30–50%) [8,24], Cyprus (34%), and Jews in Israel (42%)
[24]. The lower incidence of EBC in Egyptian women and
other developing countries may be explained. The population
structure is different with younger median population age
and lower life expectancy in developing countries [13]. Also,
there are variations in life styles and other risk factors includ-
ing genetic susceptibilities as well as screening practices [17].
Breast cancers in elderly women have some differences from
those in younger women. Among others, these differences are re-
lated to co-morbidities, tumor extension, nodal involvement,
receptor expression (ER, PR&HER-2), and biologic aggressive-
ness [16]. The current study revealed that BC in elderly Egyptian
women differs in some clinico-pathological aspects from that in
the non-elderly patients. Compared to NEBC patients, EBC pa-
tients were more likely to be smokers (0.4% vs. 0.1%, p= 0.2)
and to have a negative family history of breast cancer (1.2% vs.
2.6%, p= 0.03). Themore prevalence of a positive family history
in the younger BC patients is similar to a report on a very large
number of breast cancer patients [25]. However, due to the retro-
spective nature of the current study we could not collect data on
the number of family members affected or their age at diagnosis
or on other breast cancer risk factors.
Most patients included in the current study, whether elderly
or non-elderly, had advanced disease at presentation (stage
III–IV in 64% and 57%, respectively). This is similar to previ-
ous Egyptian reports [26]. Reasons for this may include more
genetically aggressive tumors, lack of screening programs, lack
of awareness among patients and maybe health care personnel,
or patients’ negligence [27]. The current study showed that
compared with NEBC, EBC patients were more likely to have
advanced local (i.e. T4) tumors (27% vs. 14%, p< 0.001) and
to have M1 disease (23% vs. 14%, p< 0.001). This coincides
with reports from the SEER registry and San Antonio breast
cancer databases [28], European Institute of Oncology in Mi-
lan [29], China [30] and Netherlands [31]. The ﬁnding that old-
er patients had more advanced tumors than younger patients
could be explained by a delay in the diagnosis in older patients
because of fewer breast examinations [32] and less frequent
screening mammography [33,34]. Contrary to other reports
where elderly patients had more N0 disease [28–30], LN
involvement was similar in the EBC and NEBC patients of
the current study (72% vs. 73%, respectively). This could be
related to the late presentation of Egyptian BC patients attrib-
utable to many factors [27].
The higher percentages for ILC and favorable IDC sub-
types previously reported in EBC patients compared to NEBC
patients [28] were not observed in the current study. Contrary
to many reports that showed higher ER/PR and lower HER-2
Figure 2 Sites of distant metastases in 92 elderly and 422 non-elderly breast cancer patients (CLB/LN: contra-lateral breast or lymph
node metastases).
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there were no statistically signiﬁcant differences regarding
these parameters in the current study. The reasons for this
are not known but could be attributed to genetic and biologic
differences and variations in risk factors exposure among var-
ious populations [26]. However, it should be noted that recep-
tor status, particularly HER-2, was unknown for big
proportions in the current study and the impact of this issue
cannot be estimated. Thus, these observations need to be ver-
iﬁed in prospective studies.
Elderly patients are under-represented in prospective ran-
domized trials and most of their therapeutic strategies are
extrapolated from trials of the younger patients taking in con-
sideration factors other than tumor stage and biology [17].
Similar to other reports [35,36], the current study showed that
EBC patients are less likely to be offered surgery and when sur-
gery is offered, elderly were less likely to undergo breast con-
servation. As surgery is the standard of care for the
treatment of all early BC patients, elderly patients should be
offered the same surgery as younger patients. Alternative ther-
apies should be reserved for those patients too ill or frail for
surgery, or for those who refuse it [16]. Fortunately, the
sentinel node biopsy procedure has largely solved this
problem, allowing an insight of nodal involvement without
inducing major side effects [37].
Many elderly women are denied postoperative radiotherapy
or receive it with some delay [38,39]. The current study showed
that almost 55% of EBC did not receive radiotherapy com-
pared to 27% in NEBC patients. The same pattern was also
reported in elderly BC studies [40]. Reasons like chronic ill-
nesses, long distance to radiotherapy facilities, protracted
radiotherapy course, frailty, limited social support and psycho-
logical and economic factors and patients’ or family’s prefer-
ence, all contribute to the underutilization of radiation
therapy and hence the preference of mastectomy over conserv-
ing surgeries in elderly patients. As adjuvant radiotherapy in
the elderly reduces recurrences and increases breast cancer-
speciﬁc survival [41,42], the elderly should not be denied
this treatment modality easily. Rather, the decision has to
be tailored taking in cosideration the individual ﬁtness andco-morbidities. It is also important to evaluate alternative
schedules such as partial breast irradiation [43], intra-operative
radiotherapy [44], and hypo-fractionated schedules [16].
Poly-chemotherapy may induce a signiﬁcant beneﬁt in
terms of relapse and survival rates up to 70 years of age
[45]. However, tolerability is also reduced among elderly pa-
tients [46]. In line with previous reports [28,47], EBC pa-
tients in the current study were less likely to receive
chemotherapy than the NEBC patients particularly in the
adjuvant setting. Chemotherapy should be individualized ta-
ken into account the estimated absolute beneﬁt, life expec-
tancy, treatment tolerance, and patient preference [16]. It
is recommended that adjuvant chemotherapy should not be
age-based [16] as older patients within ER-negative or
node-positive disease derive large beneﬁts of this modality
[48,49]. Four cycles of AC are preferred over CMF and both
are superior to capecitabine. Taxanes can also replace anth-
racylines to reduce cardiac risks [16]. Use of myeloid growth
factors is advisable [50]. In the metastatic setting, preference
should be given to chemotherapeutic agents with safer pro-
ﬁles. This entails choosing single rather than drug combina-
tions and those with minimal toxicities and in an adjusted
dose. These can include weekly taxanes and oral regimens
as capecitabine or vinorelbine [17].
There is no age-dependent efﬁcacy of tamoxifen or aroma-
tase inhibitors [16]. With good tolerability, ease of use and
documented beneﬁt, endocrine treatments have been com-
monly used in ER/PR positive elderly patients both in the
adjuvant and metastatic settings [17]. Similar to other reports
[30], there were no signiﬁcant differences in hormonal therapy
use between EBC and NEBC patients. Aromatase inhibitors
have a slightly greater efﬁcacy than tamoxifen and the choice
of either agent should consider their possible toxicities relevant
to the elderly e.g. cardiovascular and skeletal adverse events
with aromatase inhibitors and thrombo–embolic events or
endometrial carcinoma with tamoxifen [17].
In conclusion, the Egyptian EBC patients present with a
more advanced disease and are less likely to receive curative
therapies as surgery, radiotherapy or chemotherapy than
younger patients. Increasing awareness among patients and
Table 3 Treatments of elderly (EBC) and non-elderly breast
cancer (NEBC) in Gharbiah, Egypt.
EBC NEBC p
N % N %
Surgery 399 3036
None 83 20.8 291 9.6
Yes 316 79.2 2745 90.4 <0.001
Surgery intent
Curative 306 96.8 2662 97.0
Palliative 10 3.2 83 3.0 0.890
Surgical procedure
BCS 16 5.0 245 8.9
Mastectomy 300 95.0 2500 91.1 0.019
Radiotherapy 310 2618
None 169 54.5 701 26.8
Yes 141 45.5 1917 73.2 <0.001
Radiotherapy intent
Adjuvant 125 88.7 1819 94.9
Palliative 16 11.3 98 5.1 0.002
Adjuvant radiotherapy 247 2328
None 122 49.4 509 21.9
Yes 125 50.6 1810 78.1 <0.001
Chemotherapy 315 2637
None 115 36.5 205 7.8
Yes 200 63.5 2432 92.2 <0.001
Chemotherapy intent 250 2349
(Neo) adjuvant 162 81.0 2180 89.6
Palliative 38 19.0 252 10.4 <0.001
Adjuvant chemotherapy
None 88 35.2 169 7.2
Yes 162 64.8 2180 92.8 <0.001
Hormonal therapy 312 2480
None 129 41.3 1068 43.1
Yes 183 58.7 1412 56.9 0.563
Hormonal therapy intent
Adjuvant 158 86.3 1337 94.7
Palliative 25 13.7 75 5.3 <0.001
Adjuvant hormonal therapy 248 2200
None 90 36.3 863 39.2
Yes 158 63.7 1337 60.8 0.368
BCS: breast conservation surgery, MRM: modiﬁed radical
mastectomy.
10 A.A. Zeeneldin et al.health care professionals and adopting a screening policy can
lead to earlier detection and lower cancer-stage at diagnosis.
Treatment of elderly patients should not differ from the youn-
ger patients solely because they are ‘‘older’’.
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